1003 related articles for article (PubMed ID: 15464702)
1. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
2. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
Rodondi N; Bauer DC
Am J Med; 2004 Oct; 117(7):528-30. PubMed ID: 15464713
[No Abstract] [Full Text] [Related]
3. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
5. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
[TBL] [Abstract][Full Text] [Related]
6. Aspirin in cardiology--benefits and risks.
Björklund L; Wallander MA; Johansson S; Lesén E
Int J Clin Pract; 2009 Mar; 63(3):468-77. PubMed ID: 19222632
[TBL] [Abstract][Full Text] [Related]
7. Aspirin for the prevention of cardiovascular disease: recommendation statement.
Am Fam Physician; 2011 Jun; 83(12):1464-8. PubMed ID: 21671547
[No Abstract] [Full Text] [Related]
8. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
Waltering A; Hemkens L; Florack C
Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
[TBL] [Abstract][Full Text] [Related]
9. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
[TBL] [Abstract][Full Text] [Related]
10. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
11. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators.
Oriol-Zerbe C; Abholz HH
Eur J Gen Pract; 2007; 13(1):27-34. PubMed ID: 17366291
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA; Howard G
Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
[TBL] [Abstract][Full Text] [Related]
14. Aspirin for the primary prevention of adverse cardiovascular events.
Estes K; Thomure J
Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
U.S. Preventive Services Task Force
Am J Nurs; 2002 Mar; 102(3):67, 69-70. PubMed ID: 11976531
[No Abstract] [Full Text] [Related]
16. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
17. Aspirin overprescription in primary cardiovascular prevention.
Manes C; Giacci L; Sciartilli A; D'Alleva A; De Caterina R
Thromb Res; 2006; 118(4):471-7. PubMed ID: 16321425
[TBL] [Abstract][Full Text] [Related]
18. Aspirin use in the prevention of cardiovascular events.
Crutcher JM; Mallonee S; Daniels C
J Okla State Med Assoc; 2007 Oct; 100(10):383-7. PubMed ID: 18085095
[TBL] [Abstract][Full Text] [Related]
19. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
[TBL] [Abstract][Full Text] [Related]
20. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Wolff T; Miller T; Ko S
Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]